Self-described female-founded oncology company Phoenix Molecular Designs has started dosing in the Phase II arm of a trial examining its metastatic breast cancer candidate, PMD-026. The Phase I/Ib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback